Procter & Gamble Health Ltd (PGHL) — shareholding pattern, promoter holding, financials and share price
About Procter & Gamble Health Ltd (PGHL)
Procter & Gamble Health Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PGHL and on the BSE under scrip code 500126. Its ISIN is INE199A01012.
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. [1]
Procter & Gamble Health Limited focuses on manufacturing and marketing pharmaceuticals and chemicals, specializing in consumer health products with a strong emphasis on vitamins and supplements.
The company has demonstrated a consistent revenue growth trajectory, achieving a sales increase of 8% and profit growth of 27% over the last fiscal year, despite a challenging macroeconomic environment.
Listed peers in Pharmaceuticals: Marksans Pharma Ltd, Shilpa Medicare Ltd, Viyash Scientific Ltd, Akums Drugs & Pharmaceuticals Ltd, Blue Jet Healthcare Ltd, Sanofi Consumer Healthcare India Ltd.
Valuation & Returns
10 Jul 2026At ₹6,810 a share on 10 Jul 2026, Procter & Gamble Health Ltd (PGHL) was valued at a price-to-earnings ratio of 34.58x against an industry P/E of 36.41x and a price-to-book of 21.05x on a book value of ₹323.48 per share as of Mar 2025. Solomo computes return on equity of 60.88% and return on capital employed of 82.71% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 34.58x
- Industry P/E
- 36.41x
- P/B
- 21.05x
- EPS (TTM)
- ₹196.94
- Book value / share
- ₹323.48
- ROE
- 60.88%
- ROCE
- 82.71%
- ROA
- 41.16%
- Debt / equity
- 0.01x
- Dividend yield
- 2.28%
- EBITDA margin
- 33.67%
- 52-week range
- ₹4,699.7 – ₹6,940
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Procter & Gamble Health Ltd (PGHL) reported revenue of ₹1,408 crore, net profit of ₹327 crore and earnings per share of ₹196.94. That compares with revenue of ₹934 crore and net profit of ₹234 crore in Mar 2025 9m. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹370 crore and net profit ₹95 crore (standalone).
| Metric | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 9m | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,230 | 1,151 | 934.17 | 934 | 1,408 |
| Net profit (₹ cr) | 229 | 201 | 234.41 | 234 | 327 |
| EPS (₹) | 138.24 | 121.08 | 150.72 | 141.22 | 196.94 |
| Measure | 1Y |
|---|---|
| Sales growth | -18.86% |
| Profit growth | 16.63% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 51.82% of Procter & Gamble Health Ltd (PGHL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 6.33% and domestic institutional investors (DII) hold 12.44%. Market capitalisation was ₹11,304 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMA 4.18%, LIFE INSURANCE CORPORATION OF INDIA 1.91%, UTI-MNC FUND 1.69%, ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C 1.22%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 51.82% | - | 6.33% | 12.44% | 48.18% |
| Mar 2026 | 51.82% | - | 6.2% | 13.67% | 48.18% |
| Dec 2025 | 51.82% | - | 6.97% | 13.84% | 48.18% |
| Sep 2025 | 51.82% | - | 7.24% | 13.91% | 48.18% |
| Jun 2025 | 51.82% | - | 6.99% | 14.16% | 48.18% |
| Mar 2025 | 51.82% | - | 6.87% | 14.21% | 48.18% |
| Dec 2024 | 51.82% | - | 7.02% | 14.71% | 48.18% |
| Sep 2024 | 51.82% | - | 6.61% | 14.84% | 48.18% |